Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Klimek L, Mullol J, Reitsma S, van Gerven L, Maza-Solano J, Lundberg M, Becker S, Bärhold F, Gawlik R, Sokolowska M, Hagemann J, Akdis CA, Hox V, Toppila-Salmi S, Adcock IM, Escribese MM, Palomares O, Moreira A, Bonadonna P, Ollert M, Bousquet J, de Corso E, Shamji M, Torres MJ, Arasi S

Open source

DOI: 10.1111/all.70366
Published: 2026 Jul
Container: Allergy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/all.70366,
  title = {Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.},
  author = {Klimek L and Mullol J and Reitsma S and van Gerven L and Maza-Solano J and Lundberg M and Becker S and Bärhold F and Gawlik R and Sokolowska M and Hagemann J and Akdis CA and Hox V and Toppila-Salmi S and Adcock IM and Escribese MM and Palomares O and Moreira A and Bonadonna P and Ollert M and Bousquet J and de Corso E and Shamji M and Torres MJ and Arasi S},
  year = {2026},
  journal = {Allergy},
  doi = {10.1111/all.70366},
  url = {https://doi.org/10.1111/all.70366}
}

RIS

TY  - JOUR
TI  - Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.
AU  - Klimek L
AU  - Mullol J
AU  - Reitsma S
AU  - van Gerven L
AU  - Maza-Solano J
AU  - Lundberg M
AU  - Becker S
AU  - Bärhold F
AU  - Gawlik R
AU  - Sokolowska M
AU  - Hagemann J
AU  - Akdis CA
AU  - Hox V
AU  - Toppila-Salmi S
AU  - Adcock IM
AU  - Escribese MM
AU  - Palomares O
AU  - Moreira A
AU  - Bonadonna P
AU  - Ollert M
AU  - Bousquet J
AU  - de Corso E
AU  - Shamji M
AU  - Torres MJ
AU  - Arasi S
PY  - 2026
JO  - Allergy
DO  - 10.1111/all.70366
UR  - https://doi.org/10.1111/all.70366
ER  -

APA

L, K., J, M., S, R., L, V. G., J, M., M, L., S, B., F, B., R, G., M, S., J, H., CA, A., V, H., S, T., IM, A., MM, E., O, P., A, M., P, B., M, O., J, B., E, D. C., M, S., MJ, T., & S, A. (2026). Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.. Allergy. https://doi.org/10.1111/all.70366

Source records

pubmed · retrieved 2026-09-27T01:15:03.642Z